News

CurePSP Encourages Applications for 2014 Tau Consortium Awards

The Tau Consortium Calls for Grant Applications for Translational Research Awards to Develop Treatments for Frontotemporal Dementias and related Tau-based Disorders

The Tau Consortium (TC) is an international group of clinical and basic scientists who work together with a sense of urgency to understand, treat, and cure tau-related disorders. The organization is offering up to four major awards for translational research related to finding new treatments for frontotemporal dementia (FTD) and related tau-based disorders such as progressive supranuclear palsy (PSP). The Tau Consortium considers PSP to be a subtype of FTD and therefore eligible for this research funding. CurePSP has developed a long working relationship with the Tau Consortium - we encourage eligible candidates to submit applications for this important research opportunity.

Below is the full announcement from the Tau Consortium:



2014 Translational Awards to Develop New Treatments for Frontotemporal Dementia

The Tau Consortium (TC) is offering up to 4 major awards for translational research related to finding new treatments for frontotemporal dementia and related tau-based disorders.

Grants will be awarded for research directly geared toward developing novel therapies for frontotemporal and related dementias, with a focus on tau-based disorders, with the objective to advance the translation of scientific knowledge of underlying disease mechanisms toward benefits to patients. Specifically, the program will support translational research on known or innovative targets, with the real potential to advance discovery of therapeutic approaches in the near term. The emphasis will be on the approaches that provide a viable path toward treating these illnesses. The awards are not specifically focused to advance the understanding of the fundamental mechanisms of the disorders. Each award will be for up to $400,000 in total costs. No overhead/indirect costs are included, but may be negotiated up to a maximum of 10% taken from direct costs.

Eligibility: Candidates should be leaders of an independent research program in academia or industry and have a track record in a scientific field that can be applied to the study of new treatments for frontotemporal and related dementias. The proposal should not overlap with existing funding. However, if additional funding from this award would demonstrably facilitate the clinical development of a new treatment, such a proposal would be considered favorably. Likewise, although each award will be capped at $400,000, additional support would be considered if it would demonstrably and directly facilitate clinical development.

Application: Each grant application should consist of the application form, an NIH-style biosketch (including current funding) for each PI of the research team, plus a five page scientific proposal which describes the proposed research, including a specific plan of how the work will lead to testing a new treatment. The five page proposal (inclusive of references) must follow NIH guidelines in terms of font style, page margins, etc. A full application package must be completed by May 15, 2014. Funding decisions will be announced on or around June 1, 2014. Please submit applications in a single PDF file to rfa@tauconsortium.org. For more information about the Tau Consortium or the Consortium’s Translational Awards please visit http://www.tauconsortium.org/research/rfa.

Selection Process: All applications will be reviewed by the TC Scientific Advisory Board and Directors: Bradley Boeve (May Clinic), Eric Karran (Alzheimer’s Research UK), Kenneth Kosik (University of California Santa Barbara), Bruce Miller (University of California San Francisco), Eric Nestler, Committee Chair (Icahn School of Medicine at Mount Sinai), Everett Cook (Pouschine Cook Capital Management), and Jim Audia (Constellation Pharma).

Other Conditions: If too few suitable candidates are identified in any year, award monies will be carried forward allowing for additional awards in subsequent years. Funds may be used over a period of up to two years with annual accounting of funds spent and an annual report of research results required.

Data Replicability: In order to facilitate replicability of findings by the research community, publications should fully specify methods and grantees should ensure that all reagents, cell lines, and animal models are available, e.g., through appropriate repositories.
Good principles of research design should be employed in both animal and human studies (e.g., power calculations, appropriate statistical tests, randomization, and blinding).

Data Sharing and Publication: Applicants should include a data sharing plan with their application which is outside the five page limit. The TC wishes to promote rapid and open sharing of data with the research community.
Subject to compliance with local Institutional Review Board (IRB) and other local ethical policies aimed at protecting patient privacy, informed consent documents should be written to permit sharing of data for a wide range of research and sharing of biological samples obtained from human subjects.
Publication of findings that might affect patient care should not be unreasonably delayed.

For more information on the Tau Consortium translational research awards, please email rfa@tauconsortium.org.